跳转至内容
Merck
CN

SML2200

辛-(R)-2HG

≥98% (HPLC), film, α-KG-dependent dioxygenases prolyl hydroxylases inhibitor

别名:

(2R)-2-羟基戊二酸辛酯, (2R)-辛基-α-羟基戊二酸, 1-辛基-D-2-羟基戊二酸盐, 1-辛基酯, R-2HG 辛基酯, 羟基戊二酸, 辛-D-2HG, 辛基-2HG

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C13H24O5
化学文摘社编号:
分子量:
260.33
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

辛-(R)-2HG, ≥98% (HPLC)

SMILES string

O[C@H](CCC(=O)O)C(=O)OCCCCCCCC

InChI key

UJZOKTKSGUOCCM-LLVKDONJSA-N

assay

≥98% (HPLC)

form

film

storage condition

desiccated

color

colorless

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Application

辛基-(R)-2羟基戊二酸酯(HG)已被用作胶质母细胞瘤细胞中的膜渗透性致癌代谢物(oncometabolite),用于测试其对NANOG转录因子表达的影响。它还被用作酮戊二酸酯(α-KG)依赖性脱氧酶α的竞争性抑制剂。

Biochem/physiol Actions

抑制 α-酮戊二酸/α-KG 依赖性双加氧酶类的肿瘤代谢产物 D-2-羟基戊二酸的膜渗透前体形式。
辛基-(R)-2HG (Octyl-D-2HG) 是肿瘤细胞因 NADP + 依赖性异柠檬酸脱氢酶基因 IDH1 和 IDH2 突变而产生的肿瘤代谢产物 D-2-羟基戊二酸盐 (D-2HG) 的膜渗透前体形式。D-2HG 通过与 α-KG 结合竞争抑制多种 α-酮戊二酸/α-KG-依赖性双加氧酶。通过 Octyl-(R)-2HG 处理 (1-50 mM) 的细胞 D-2HG 传递显示出抑制脱甲基酶活性(~148%H3K9me2 和 ~310%H3K79me2 上调;U-87 mg 中 50 mm)以及因为分别抑制 α-KG-依赖性双加氧酶脯氨酰羟化酶 (PHD) 和胶原脯氨酰-4-羟化酶 (C-P4H)而增加 HIF-1α通过, 降低内皮抑素水平。

Preparation Note

该化合物未报告密度。分子量为260.33。DMSO中的溶解性经测试为2 mg/mL,然而其他数据来源表明其在DMSO中的溶解度可高达10 mg/mL。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

alpha-Ketoglutarate-Activated NF-$\kappa$B Signaling Promotes Compensatory Glucose Uptake and Brain Tumor Development
Wang X, et al.
Molecular Cell, 76(1), 148-162 (2019)
Zachary J Reitman et al.
The Journal of biological chemistry, 289(34), 23318-23328 (2014-07-06)
Mutations in the cytosolic NADP(+)-dependent isocitrate dehydrogenase (IDH1) occur in several types of cancer, and altered cellular metabolism associated with IDH1 mutations presents unique therapeutic opportunities. By altering IDH1, these mutations target a critical step in reductive glutamine metabolism, the
Jing-Yi Chen et al.
Scientific reports, 6, 32428-32428 (2016-09-01)
Mutations of isocitrate dehydrogenase 1 (IDH1) and IDH2 in acute myeloid leukemia (AML) cells produce the oncometabolite R-2-hydroxyglutarate (R-2HG) to induce epigenetic alteration and block hematopoietic differentiation. However, the effect of R-2HG released by IDH-mutated AML cells on the bone
Parker L Sulkowski et al.
Science translational medicine, 9(375) (2017-02-06)
2-Hydroxyglutarate (2HG) exists as two enantiomers, (R)-2HG and (S)-2HG, and both are implicated in tumor progression via their inhibitory effects on α-ketoglutarate (αKG)-dependent dioxygenases. The former is an oncometabolite that is induced by the neomorphic activity conferred by isocitrate dehydrogenase
Makoto Hirata et al.
Proceedings of the National Academy of Sciences of the United States of America, 112(9), 2829-2834 (2015-03-03)
Enchondromas are benign cartilage tumors and precursors to malignant chondrosarcomas. Somatic mutations in the isocitrate dehydrogenase genes (IDH1 and IDH2) are present in the majority of these tumor types. How these mutations cause enchondromas is unclear. Here, we identified the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持